A Phase I Study of XH-S004 in Healthy Volunteers - Trial NCT06236841
Access comprehensive clinical trial information for NCT06236841 through Pure Global AI's free database. This Phase 1 trial is sponsored by S-Infinity Pharmaceuticals Co., Ltd and is currently Not yet recruiting. The study focuses on Healthy Adults. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
S-Infinity Pharmaceuticals Co., Ltd
Timeline & Enrollment
Phase 1
Jan 26, 2024
Jan 31, 2025
Primary Outcome
To access the incidence and severity of adverse events (AEs), serious AEs and abnormalities on laboratory tests [Safety and Tolerability] of single ascending oral dose of XH-S004 in healthy adults.,To access the incidence and severity of adverse events (AEs), serious AEs and abnormalities on laboratory tests [Safety and Tolerability] of multiple ascending oral dose of XH-S004 in healthy adults.
Summary
This is a phase I, randomised, double-blind placebo-controlled, 3-part study to assess the
 safety, tolerability, pharmacokinetics and food effect of single and multiple oral doses of
 XH-S004 in healthy volunteers.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06236841
Non-Device Trial